相关实验视频

Updated: May 9, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

调整CAR表面密度和动态,以改善CAR-T细胞疗法

Ana Hinckley-Boned¹, Carmen Barbero-Jiménez^2,3, Maria Tristán-Manzano^1,2,4,5

¹Department of Genomic Medicine, Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain.

Journal for immunotherapy of cancer

|April 29, 2025

概括

调节细胞膜上的化学抗原受体 (CAR) -T细胞治疗蛋白质密度可以提高疗效,克服复发率和有限的固体瘤活性等挑战.

科学领域:

免疫治疗是一种免疫疗法.
细胞疗法细胞疗法
在瘤学瘤学.

背景情况:

化学抗原受体 (CAR) -T细胞疗法已被批准用于B细胞新生体,但面临挑战,包括复发和有限的固体瘤疗效.
目前的CAR-T方法在血液恶性瘤中具有30-50%的复发率和显著的副作用.

研究的目的:

探索调节细胞膜上的CAR蛋白密度的治疗潜力,以改善CAR-T细胞治疗结果.
审查影响CAR表面表达和CAR下调动态的因素.

主要方法:

对CAR-T细胞疗法的当前文献的综述,重点关注CAR表面表达动态.
分析影响CAR蛋白密度的因素,包括CAR下调和抗原相互作用.
探索控制CAR表达的策略,例如转录控制和CAR设计修改.

主要成果:

CAR蛋白质密度受到抗原接触和CAR下调的影响,这仍然未得到充分研究.
修改CAR下调是一种提高CAR-T细胞功能的潜在策略.
转录控制和特定的CAR设计元素提供了量身定制CAR表达特征的方法.

结论:

控制细胞表面上CARs的动态密度是一个有前途的策略,以优化CAR-T细胞疗法的治疗结果.
对CAR下调调节机制和表达控制的进一步研究是有必要的,以提高CAR-T细胞的疗效和安全性.
准CAR蛋白密度提供了一种新的方法来增强血液和固体瘤的CAR-T细胞疗法.

关键词:

抗原受体设计的设计化学抗原受体 - - CAR 免疫治疗是一种免疫疗法.固体瘤是一个固体瘤.T细胞受体 - - TCR 细胞受体

更多相关视频

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cell-surface Signaling

Cell-surface Signaling

Hormones—or any molecule that binds to a receptor, known as a ligand—that are lipid-insoluble (water-soluble) are not able to diffuse across the cell membrane. In order to be able to affect a cell without entering it, these hormones bind to receptors on the cell membrane. When a first messenger, a hormone, binds to a receptor, a signal cascade is set off, causing second messengers, proteins inside the cell, to become activated, resulting in downstream effects.